• Home
  • NEW DAY MEDICINE
  • 1(39)2022
  • 26 -1 (39) 2022 — Madaminov G.G., Babadjanova N.R., — RHEOLOGICAL STATE OF THE BLOOD AND CLINICAL AND PATHOGENETIC FEATURES OF DISEASES OF THE HEMOSTASIS SYSTEM IN PATIENTS ON PROGRAM HEMODIALISM

26 -1 (39) 2022 — Madaminov G.G., Babadjanova N.R., — RHEOLOGICAL STATE OF THE BLOOD AND CLINICAL AND PATHOGENETIC FEATURES OF DISEASES OF THE HEMOSTASIS SYSTEM IN PATIENTS ON PROGRAM HEMODIALISM

RHEOLOGICAL STATE OF THE BLOOD AND CLINICAL AND PATHOGENETIC FEATURES OF DISEASES OF THE HEMOSTASIS SYSTEM IN PATIENTS ON PROGRAM HEMODIALISM

Madaminov G.G., Andijan Regional Multidisciplinary Medical Center,Republican Specialized Scientific and Practical Medical Center for Nephrology and Kidney Transplantation,Tashkent State Dental Institute

Babadjanova N.R., Andijan Regional Multidisciplinary Medical Center,Republican Specialized Scientific and Practical Medical Center for Nephrology and Kidney Transplantation,Tashkent State Dental Institute

Tashpulatova M.X., Andijan Regional Multidisciplinary Medical Center,Republican Specialized Scientific and Practical Medical Center for Nephrology and Kidney Transplantation,Tashkent State Dental Institute

Isirgapova S.N. Andijan Regional Multidisciplinary Medical Center,Republican Specialized Scientific and Practical Medical Center for Nephrology and Kidney Transplantation,Tashkent State Dental Institute

Resume

The article discusses the three-month dynamics of hemostasis in 101 patients with end-stage chronic kidney disease receiving program dialysis, as well as the mechanisms of cardiovascular diseases and other thromboembolic complications caused by hemostasis, the problems of their modern diagnosis.

Key words: chronic kidney disease, programmed hemodialysis, hemostasis, thromboembolism, fibrinogen, thrombin test, platelet reactivation time, D-dimer.

First page

130

Last page

134

For citation: Madaminov G.G., Babadjanova N.R., Tashpulatova M.X., Isirgapova S.N. RHEOLOGICAL STATE OF THE BLOOD AND CLINICAL AND PATHOGENETIC FEATURES OF DISEASES OF THE HEMOSTASIS SYSTEM IN PATIENTS ON PROGRAM HEMODIALISM //New Day in Medicine 1(39)2022 130-134 https://cutt.ly/FObD1qT

LIST OF REFERENCES:

  1. Козловская Н.Л. Низкомолекулярные гепарины в профилактике и лечение тромбозов у пациентов с хронической болезнью почек. // «Эффективная фармакотерапия урология и нефрология» 2020 г. [Kozlovskaya N.L. Nizkomolekulyarnyye gepariny v profilaktike i lecheniye trombozov u patsiyentov s khronicheskoy bolezn’yu pochek. // «Effektivnaya farmakoterapiya urologiya i nefrologiya» 2020 g.]
  2. Мельник А.А, Почки, p-ISSN 2307-1257, e-ISSN 2307-1265 №3(17) 2016г. [Mel’nik A.A, Pochki, p-ISSN 2307-1257, e-ISSN 2307-1265 №3(17) 2016g.]
  3. Томилина Н.А., Хроническая болезнь почек, избранные главы нефрологии, 2017г. 117-118 ст. [Tomilina N.A., Khronicheskaya bolezn’ pochek, izbrannyye glavy nefrologii, 2017g. 117-118 st.]
  4. Шилов  А.М.,  Мельник  М.В.,  Осия  А.О.,  Свири-дова  А.Ю.,  Мельник  Н.В.  Патофизиология  и принципы  лечения  фибрилляции  предсердий //  Русский  Медицинский  Журнал.  –  2011.  – № 14. – C.877–883. [Shilov  A.M.,  Mel’nik  M.V.,  Osiya  A.O.,  Sviri-dova  A.YU.,  Mel’nik  N.V.  Patofiziologiya  i printsipy  lecheniya  fibrillyatsii  predserdiy //  Russkiy  Meditsinskiy  Zhurnal.  –  2011.  – № 14. – C.877–883.]
  5. Adcock D.M., Gosselin R. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review Thrombosis Research136 (2015): 7–12.
  6. Alonso  A.,  Lopez  F.L.,  Matsushita  K.,  Loehr L.R.,  Agarwal  S.K.,  Chen  L.Y.,  Soliman  E.Z., Astor  B.C.,  Coresh  J.  Chronic  kidney  disease  is associated  with  the  incidence  of  atrial  fibrillation: the  Atherosclerosis  Risk  in  Communities  (ARIC) study.  Circulation.  2011  Jun  28;  123  (25):  2946–53.
  7. Ando M., Iwata A., Ozeki Y., et al. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int 2002. 62:1757–63.
  8. Campos  B.,  Lee  T.,  Roy-Chaudhury  P.  Arteriovenous fistula failure: is there a role for epigenetic regulation? SeminNephrol. 2013; 33:400–406.
  9. Chou C.Y., Kuo H.L., Yung Y.F., et al. C-reactive protein predicts vascular access thrombosis in hemodialysis patients. Blood Purif 2006. 24:342-6.
  10. Douma R.A., le Gal G., Söhne M., Righini M., Kamphuisen P.W., Perrier A., Kruip M.J., Bounameaux H., Büller H.R., Roy P.M. Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts. // BMJ (Clinical research ed.). — 2010. — Vol. 340. — P. 1475.
  11. Fesmire F.M., Brown M.D., Espinosa J.A., Shih R. D., Silvers S.M., Wolf S.J., Decker W.W. Critical issues in the evaluation and management of adult patients presenting to the emergency department with suspected pulmonary embolism. // Annals of emergency medicine. — 2011. — Vol. 57, no.6. – P. 628-652. – doi:10.1016/j.annemergmed.2011.01.020. — PMID 21621092. 
  12. General Practice Notebook > D-dimer Retrieved September – 2011.
  13. Hylek E.M. Anticoagulation therapy for atrial fibrillation Semin Thromb Hemost.2013; 39(2): 147–152
  14. Lok C.E., Moist L., Hemmelgarn B.R., et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial. JAMA 2012. 307:1809-16.
  15. Misra S., Fu A.A., Rajan D.K., et al. Expression of hypoxia inducible factor-1 alpha, macrophage migration inhibition factor, matrix metalloproteinase-2 and – 9, and their inhibitors in hemodialysis grafts and arteriovenous fistulas. //J Vasc Interv Radiol 2008. 19:252-9.
  16. Montagnana  M,  Meschi  T,  Borghi  L,  et  al. Thrombosis  and  occlusion  of  vascular  access  in hemodialyzed patients. Semin Thromb Hemost 2011; 37:946 –54.
  17. Ment J. Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. Vascular Health and Risk Management 2015: 11; 317–332.
  18. Barnoev Khabib  The State of Renal Functional Reserve During the Predialysis Stages of Chronic Kidney Disease // American Journal of Medicine and Medical Sciences 2021, 11(4): 316-321  DOI: 10.5923/j.ajmms.20211104.13
  19. Palmer S.C., Di Micco L., Razavian M., et al. Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis. Am J Kidney Dis 2013. 61:112–22.
  20. Quencer  K.B.,  Kidd  J,  Kinney  T.  Preprocedure Evaluation  of  a Dysfunctional  Dialysis  Access. Tech VascInterv Radiol 2017; 20:20–30.

file

download